Paragon Bioservices
Baltimore
About Paragon Bioservices
Paragon Bioservices is an industry-leading, private-equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of cutting-edge biopharmaceuticals. Paragon aims to build strong client partnerships with the world’s best biotech and pharma companies, focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, oncology immunotherapies (oncolytic viruses and CAR-T cell therapies), therapeutic proteins, and other complex biologics. The Company’s customer base has also transitioned from primarily substantial government contracts to now focus almost 100% on commercial activity servicing the biotech marketplace. The Company has retained Paragon’s core scientific talent while expanding its leadership team with new key senior hires who have a proven track record in GMP manufacturing. Each member of the current leadership team has over 20 years of industry experience and serves as the Company’s foundation to build a dominant CDMO in Maryland. Paragon now provides complete manufacturing services from process development and clinical manufacturing through commercial launch at its new 150,000 ft2 facility.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 251 – 500
- Estimated revenue: $50K – $100K
- Total funding: $20.0M
- Funding stage: M&A
- Last round: Series Unknown (Aug 2018)
- Website: paragonbioservices.com
- Phone: (410) 975-4050
Industries & Categories
Biotechnology, Clinical Trials, Manufacturing
Social Profiles
Canonical: https://fsome.com/organization/paragon-bioservices-29378 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.